Table 1 Patient characteristics
(n = 78) | ||
|---|---|---|
Age (years) | 70 (50–88) | |
PSA at PCa diagnosis (ng/mL) | 124.6 (4.7-19523.1) | |
PSA at DTX initiation (ng/mL) | 19.7 (0.6-1053.0) | |
Time from PCa diagnosis to DTX initiation (months) | 37 (4–189) | |
PSADT (months) | 2.4 (0.6-33.9) | |
ECOG performance status, n (%) | ||
0 | 40 (51) | |
1 | 28 (36) | |
2 | 10 (13) | |
Gleason score, n (%) | ||
<6 | 5 (6) | |
7 | 16 (21) | |
>8 | 50 (64) | |
Unknown | 7 (9) | |
Metastatic site, n (%) | ||
Bone | 42 (54) | |
Lymph nodes | 19 (24) | |
Liver | 3 (4) | |
Lung | 1 (1) | |
None | 28 (36) | |
Bone scan progression, n (%) | ||
Yes | 15 (19) | |
No | 63 (81) | |
Pain at baseline, n (%) | ||
Yes | 24 (31) | |
No | 54 (69) | |
Haemoglobin (g/dL) | 11.8 (8.4-14.1) | |
ALP (IU/L) | 290 (59–8689) | |
Prior treatment, n (%) | ||
Combined androgen blockade | 78 (100) | |
Prostatectomy | 3 (4) | |
Radiotherapy | 10 (13) | |
Estramustine | 69 (88) | |
No. of DTX cycles | 5 (2–46) | |